Tumor therapeutic agent and kit containing gemcitabine liposome composition

Abstract

An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

What is claimed is: 
     
         1 . A method of suppressing the growth of a human pancreatic cancer cell, comprising:
 administering a liposome composition in which gemcitabine or a salt thereof is contained in a liposome, and   administering nab-paclitaxel.   
     
     
         2 . The method according to  claim 1 , wherein a lipid forming the liposome contains hydrogenated soybean phosphatidylcholine, 1,2-distearoyl-3-phosphatidylethanolamine-polyethylene glycol, and cholesterol. 
     
     
         3 . The method according to  claim 1 , wherein the liposome is a single lamella. 
     
     
         4 . The method according to  claim 1 , wherein a release rate of gemcitabine or a salt thereof from the liposome composition in plasma is 10 mass %/24 hr to 70 mass %/24 hr. 
     
     
         5 . The method according to  claim 1 , wherein a content ratio of cholesterols to a total amount of the lipid forming the liposome is 10 mol % to 35 mol %, and an osmotic pressure of an inner aqueous phase of the liposome is 2 to 8 times an osmotic pressure of an outer aqueous phase of the liposome. 
     
     
         6 . The method according to  claim 1 , wherein an average particle diameter of the liposome is 2 nm to 200 nm.